首页 › 弥漫性大B细胞淋巴瘤 › 田纳西州 › Nashville
Nashville TN 弥漫性大B细胞淋巴瘤临床试验
17项针对 弥漫性大B细胞淋巴瘤的研究正在 Nashville及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
招募中1/2 期
- SCRI Oncology Partners ( Site 0100), Nashville
- Henry-Joyce Cancer Clinic ( Site 0115), Nashville
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
招募中3 期
- SCRI Oncology Partners ( Site 7000), Nashville
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
招募中2 期
- SCRI Oncology Partners ( Site 7002), Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
招募中2 期
- Tennessee Oncology, Nashville
A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
招募中1 期
- SCRI Oncology Partners, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- SCRI Oncology Partners, Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
招募中1 期
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
招募中2 期
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
招募中1/2 期
- TriStar BMT, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
招募中1 期
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Tennessee Oncology, Pllc Nashville, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
招募中2 期
- Vanderbilt University/Ingram Cancer Center, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
招募中1/2 期
- Sarah Cannon Research Institute, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
招募中1/2 期
- Vanderbilt University Medical Center, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- SCRI Oncology Partners, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
招募中1 期
- Tennessee Oncology, Nashville
其他城市的 弥漫性大B细胞淋巴瘤试验
- New York City, NY20 项研究
- Baldwin Park, CA19 项研究
- Los Angeles, CA18 项研究
- Houston, TX18 项研究
- Chicago, IL18 项研究
- Milwaukee, WI17 项研究
- Boston, MA17 项研究
- Philadelphia, PA15 项研究
- Durham, NC15 项研究
- Portland, OR15 项研究
- Cleveland, OH13 项研究
- Seattle, WA13 项研究
Nashville的其他研究
- 非小细胞肺癌97 项研究
- 乳腺癌78 项研究
- 转移性癌症69 项研究
- 结直肠癌67 项研究
- 癌症（所有类型）65 项研究
- 卵巢癌50 项研究
- 头颈鳞状细胞癌43 项研究
- 前列腺癌40 项研究
- 胰腺癌39 项研究
- 肺癌39 项研究
- 子宫内膜癌38 项研究
- 黑色素瘤34 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。